NEW NANOTHERAPY RESEARCH FOR INFLAMMATORY BOWEL DISEASES

THE NEW DEAL CONCEPT COULD REVOLUTIONIZE IBD THERAPIES FOR THE GREAT BENEFIT OF PATIENTS AND EUROPEAN HEALTHCARE SYSTEMS.

  • Dr. Fabrice NAVARRO, New Deal Project Coordinator

THE PROJECT GOALS

The NEW DEAL project aims to develop a highly selective and local therapy with an improved efficacy and safety profile for IBD patients. This treatment might be an alternative to the existing therapies.

Design and validate a radically improved IBD therapy that specifically targets JAK1 / JAK3 inhibition by means of siRNA and RNAi interference.

Develop advanced technologies for delivering siJAK1 / siJAK3 locally to the inflamed gut

Promote the clinical translation and the future industrial transfer of this new clinical product for IBD therapy.

THE PROJECT NEWS

March New Deal Reads

March 5th, 2020|

Lipid-based nanoformulations in the treatment of neurological disorders. Pottoo et al. 2020. Drug Metabolism Reviews.    Neurological disorders [...]

February New Deal Reads

February 26th, 2020|

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease. Sandborn et al. 2020. [...]

September New Deal Reads

September 10th, 2019|

1. siRNA Delivery for Control of Cyclin D1 and E2F1 Expression in Crohn's Disease. Russo I. et al. 2017. Transl Med [...]

More news

THE PROJECT PARTNERS

From 2017 to 2018